#8 - Oracle (NYSE:ORCL)
The race is on to find a workable vaccine and treatments for the coronavirus. The sooner the world has effective treatments, the sooner the economy can return to normal. Oracle (NYSE:ORCL) is at the forefront of this race.
The company is creating, and donating, a website and mobile apps that will allow the government to collect data on the treatment of the coronavirus using antimalarial drugs. The government will maintain oversight of the project.
The use of data will be key to convincing healthcare officials that antimalarial drugs have more than circumstantial evidence of effectiveness.
"Many of the things that you hear out there are what I had called anecdotal reports," White House Coronavirus Task Force member Anthony Fauci said on the antimalarial drugs on Saturday, as per the Post.
"They may be true, but they're anecdotal. So the only thing that I was saying is that if you really want definitively to know if something works, that you've got to do the kind of trial that you get, the good information."
About Oracle
Oracle Corporation offers products and services that address enterprise information technology environments worldwide. Its Oracle cloud software as a service offering include various cloud software applications, including Oracle Fusion cloud enterprise resource planning (ERP), Oracle Fusion cloud enterprise performance management, Oracle Fusion cloud supply chain and manufacturing management, Oracle Fusion cloud human capital management, Oracle Cerner healthcare, Oracle Advertising, and NetSuite applications suite, as well as Oracle Fusion Sales, Service, and Marketing.
Read More - Current Price
- $192.29
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 18 Buy Ratings, 11 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $169.52 (11.8% Downside)
